Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H26N4O |
Molecular Weight | 386.4894 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC=C1CN2C3=NCCN3C4=C(CN(CC5=CC=CC=C5)CC4)C2=O
InChI
InChIKey=VLULRUCCHYVXOH-UHFFFAOYSA-N
InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
Molecular Formula | C24H26N4O |
Molecular Weight | 386.4894 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 20:21:39 UTC 2023
by
admin
on
Sat Dec 16 20:21:39 UTC 2023
|
Record UNII |
9U35A31JAI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
553316
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
||
|
FDA ORPHAN DRUG |
640218
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LM-148
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
1342897-86-2
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
SUPERSEDED | |||
|
C113792
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
73777259
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
9U35A31JAI
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
12147
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
300000017123
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
1616632-77-9
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
DB14844
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY | |||
|
350625
Created by
admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
ANTAGONIST
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Experiments showed that TIC10 had potent effects against a variety of tumours, including breast, lymphatic, colon and lung cancer. It was especially effective at triggering cell suicide in glioblastoma, a kind of brain tumour that is notoriously difficult to treat2. Mice with glioblastomas that were treated with TIC10 in combination with bevacizumab a drug used against diseases including brain tumours, and sold under the name Avastin survived three times as long as untreated mice. Even mice treated with TIC-10 alone still had better survival rates (6% longer) than those treated with bevacizumab alone.
|